Literature DB >> 24301337

Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.

Yi-Chen Yeh1, Teh-Ying Chou.   

Abstract

BACKGROUND AND OBJECTIVES: Pulmonary neuroendocrine tumors have a prognostic spectrum including typical carcinoid (TC), atypical carcinoid (AC), small cell carcinoma (SCLC), and large cell neuroendocrine carcinoma (LCNEC). We conducted a retrospective study to compare their clinicopathological characteristics, immunophenotype, preoperative biopsy and frozen section diagnoses, and prognosis.
METHODS: Ninety cases of surgically treated pulmonary neuroendocrine tumors were studied. Immunohistochemical studies were performed using antibodies to chromogranin A, synaptophysin, and CD56. The preoperative biopsy and frozen section diagnoses were reviewed.
RESULTS: The 5-year survival rates for TC, AC, SCLC, and LCNEC were 96.6%, 66.7%, 42.4%, and 38.0%, respectively. T stage and pleural status correlated with outcome of SCLC and LCNEC, but N-stage and overall TNM stage did not. In preoperative biopsy, accurate diagnosis was achieved in 5 of 11 TC, 2 of 4 AC, 6 of 15 SCLC, and 0 of 5 LCNEC cases. Using frozen sections, accurate diagnosis was achieved in 8 of 12 TC, 2 of 11 SCLC, and 0 of 11 LCNEC cases.
CONCLUSIONS: LCNEC was the most difficult to diagnose using either preoperative biopsy or frozen sections. T stage and pleural status can predict outcome of SCLC and LCNEC.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  frozen section; immunohistochemistry; lung; neuroendocrine; prognosis

Mesh:

Substances:

Year:  2013        PMID: 24301337     DOI: 10.1002/jso.23497

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  9 in total

Review 1.  Neuroendocrine Pulmonary Tumors of Low, Intermediate and High Grade: Anatomopathological Diagnosis-Prognostic and Predictive Factors.

Authors:  José Manuel Cameselle-Teijeiro; José Antonio Mato Mato; Ovidio Fernández Calvo; Jesús García Mata
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

2.  Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.

Authors:  P Lecomte; C Binquet; M Le Bras; A Tabarin; C Cardot-Bauters; F Borson-Chazot; C Lombard-Bohas; E Baudin; B Delemer; M Klein; B Vergès; T Aparicio; E Cosson; A Beckers; Ph Caron; O Chabre; Ph Chanson; H Du Boullay; I Guilhem; P Niccoli; V Rohmer; J Guigay; C Vulpoi; J Y Scoazec; P Goudet
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

3.  Predictive factors of postoperative survival among patients with pulmonary neuroendocrine tumor.

Authors:  Yoshinobu Ichiki; Hiroki Matsumiya; Masataka Mori; Masatoshi Kanayama; Yusuke Nabe; Akihiro Taira; Shinji Shinohara; Taiji Kuwata; Masaru Takenaka; Ayako Hirai; Naoko Imanishi; Kazue Yoneda; Hiroshi Noguchi; Shohei Shimajiri; Yoshihisa Fujino; Toshiyuki Nakayama; Fumihiro Tanaka
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

4.  Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis.

Authors:  Shuwen Zhang; Jingjing Chen; Rui Zhang; Liqin Xu; Yan Wang; Zaixin Yuan; Xiaohui Hou; Jian Feng
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-06       Impact factor: 4.553

5.  CDX2 Expression and Prognostic Factors of Resectable Pulmonary Large Cell Neuroendocrine Carcinoma.

Authors:  Ryo Mori; Shin-Ichi Yamashita; Kensuke Midorikawa; Sosei Abe; Kazuo Inada; Satoshi Yoneda; Kan Okabayashi; Kazuki Nabeshima
Journal:  Clin Med Insights Oncol       Date:  2020-11-26

6.  Construction and validation of nomograms based on the log odds of positive lymph nodes to predict the prognosis of lung neuroendocrine tumors.

Authors:  Suyu Wang; Juan Wei; Yibin Guo; Qiumeng Xu; Xin Lv; Yue Yu; Meiyun Liu
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

7.  Large-cell neuroendocrine carcinoma (LCNEC) without pulmonary symptoms diagnosed in a cutaneous metastasis.

Authors:  Cai Yuan; Benjamin Keating; Laurie A Farricielli; Kuixing Zhang
Journal:  Am J Case Rep       Date:  2014-03-04

8.  Low-Dose Nicotine Activates EGFR Signaling via α5-nAChR and Promotes Lung Adenocarcinoma Progression.

Authors:  Mong-Lien Wang; Yi-Fan Hsu; Chih-Hsuan Liu; Ya-Ling Kuo; Yi-Chen Chen; Yi-Chen Yeh; Hsiang-Ling Ho; Yu-Chung Wu; Teh-Ying Chou; Cheng-Wen Wu
Journal:  Int J Mol Sci       Date:  2020-09-17       Impact factor: 5.923

9.  Expression of neuro-oncological ventral antigen-1 in small-cell lung cancer and its value in pathological diagnosis.

Authors:  Shuangshuang Deng; Meixuan Liu; Tianyu Xiao; Jinli Gao
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.